Prakt. lékáren. 2018; 14(2): 67-69 | DOI: 10.36290/lek.2018.012

Therapeutic drug monitoring in clinical practice

Hana Suchánková1,2
1 Oddělení geriatrie, Fakultní nemocnice Olomouc
2 Ústav farmakologie, Lékařská fakulta, Univerzita Palackého v Olomouci

To optimise patients’outcomes of pharmacotherapy, special attention should be given to dosing selection. Therapeutic drugmonitoring (TDM) is a dosing individualisation strategy that helps to minimise toxicity whilst maximising the efficacy of the agentand helps to reduce the health care costs. To optimise dosing, pharmacokinetic characteristics and pharmacodynamic target ofthe agent must be considered. The aim of this paper is to review the role of TDM in clinical practice, summarise characteristicsof drugs suitable for TDM and identify patients that would most likely benefit from it, outline limitations of methods used tomeasure drug concentrations, describe dosing adjustments strategies and finally discuss the concentration-effect relationshipand therapeutic targets of antimicrobials.

Keywords: TDM, pharmacokinetics, dosing regimen, concentration

Published: June 20, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Suchánková H. Therapeutic drug monitoring in clinical practice. Praktické lékárenství. 2018;14(2):67-69. doi: 10.36290/lek.2018.012.
Download citation

References

  1. Bakt?r G. Therapeutic drug monitoring (TDM). Lectio Sci 2017; 1: 54-65.
  2. Eliasson E, Lindh JD, Malmström RE, Beck O, Dahl M-L. Therapeutic drug monitoring for tomorrow. Eur J Clin Pharmacol 2013; 69 Suppl 1: 25-32. Go to original source... Go to PubMed...
  3. Hiemke C, Bergemann N, Clement HW, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2017.
  4. Roberts JA, Norris R, Paterson DL, Martin JH. Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol 2012; 73: 27-36. Go to original source... Go to PubMed...
  5. Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother 2014; 69: 1162-1176. Go to original source... Go to PubMed...
  6. Ghiculescu RA. Therapeutic drug monitoring: which drugs, why, when and how to do it. Aust Prescr 2008; 31: 42-44. Go to original source...
  7. Rane CT, Dalvi SS, Gogtay NJ, Shah PU, Kshirsagar NA. A pharmacoeconomic analysis of the impact of therapeutic drug monitoring in adult patients with generalized tonic-clonic epilepsy. Br J Clin Pharmacol 2001; 52: 193-195. Go to original source... Go to PubMed...
  8. Streetman DS, Nafziger AN, Destache CJ, Bertino AS. Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs. Pharmacotherapy 2001; 21: 443-451. Go to original source... Go to PubMed...
  9. Ye Z-K, Tang H-L, Zhai S-D. Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis. PloS One 2013; 8: e77169. Go to original source... Go to PubMed...
  10. Touw DJ, Neef C, Thomson AH, Vinks AA, Cost-Effectiveness of Therapeutic Drug Monitoring Committee of the International Association for Therapeutic Drug Monitoring and Clinical Toxicology. Cost-effectiveness of therapeutic drug monitoring: a systematic review. Ther Drug Monit 2005; 27: 10-17. Go to original source... Go to PubMed...
  11. Martelli L, Olivera P, Roblin X, Attar A, Peyrin-Biroulet L. Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review. J Gastroenterol 2017; 52: 19-25. Go to original source... Go to PubMed...
  12. Carlier M, Stove V, Wallis SC, et al. Assays for therapeutic drug monitoring of ?-lactam antibiotics: A structured review. Int J Antimicrob Agents 2015; 46: 367-375. Go to original source... Go to PubMed...
  13. Fuchs A, Csajka C, Thoma Y, Buclin T, Widmer N. Benchmarking therapeutic drug monitoring software: a review of available computer tools. Clin Pharmacokinet 2013; 52: 9-22. Go to original source... Go to PubMed...
  14. Neely MN, Youn G, Jones B, et al. Are Vancomycin Trough Concentrations Adequate for Optimal Dosing? Antimicrob Agents Chemother 2014; 58: 309-316. Go to original source... Go to PubMed...
  15. Reeves D, Lovering A, Thomson A. Therapeutic drug monitoring in the past 40 years of the Journal of Antimicrobial Chemotherapy. J Antimicrob Chemother 2016; 71: 3330-3332. Go to original source... Go to PubMed...
  16. Kacířová I, Grundmann M. TDM antibiotik v klinické praxi. Kardiologická Rev - Interní Medicína 2015; 17: 57-64.
  17. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm 2009; 66: 82-98. Go to original source... Go to PubMed...
  18. Pai MP, Neely M, Rodvold KA, Lodise TP. Innovative approaches to optimizing the delivery of vancomycin in individual patients. Adv Drug Deliv Rev 2014; 77: 50-57. Go to original source...
  19. Suchánková H, Machačová M, Herodesová T. Terapeutické monitorování vankomycinu v klinické praxi. Klin Farmakol Farm 2016; 30: 4-8. Go to original source...
  20. Huttner A, Harbarth S, Hope WW, Lipman J, Roberts JA. Therapeutic drug monitoring of the ?-lactam antibiotics: what is the evidence and which patients should we be using it for? J Antimicrob Chemother 2015; 70: 3178-3183. Go to original source... Go to PubMed...
  21. Suchánková H, Matušková Z, Vanduchová A. Terapeutické monitorování beta-laktamových antibiotik. Klin Mikrobiol Infekcni Lek 2017; 23.




Pharmacy for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.